The court found that Actavis requires refund comparisons to contain money, in part because the majority and differing opinions “stink after discussion about paying the money.” 9 Since the transaction similar to a dispute did not contain money, it was not regarded as a refund. As a result, the first part of the examination was not completed, an examination by Actavis was not necessary and the request for rejection for non-investigation of a claim was accepted. The court also found that the deal would have survived even if it had been considered as part of the “five reflections” of the test rule of Reason.10 The FTC`s Amicus letter states that the Effexor XR case “is an issue with a significant impact on U.S. consumers”: the question of whether pharmaceutical patent comparisons are “immune to antitrust scrutiny as long as the manufacturer of branded products for deferred entry with something else “s in cash”. The letter explains why “the allegations here raise the same type of anti-dominant concern identified by the Supreme Court at Actavis” and should therefore be treated in the same way. The Supreme Court`s opinion speaks of “payments” and “money,” not because cash has a unique economic effect, but because Actavis contained allegations of cash payments. Critics of the FTC`s position argue that reimbursement schemes are legitimate dispute resolution mechanisms that cannot affect competition unless the transaction excludes competition that goes beyond the scope of a patent in force. The courts agreed by an overwhelming majority. Critics also point to two weaknesses in the FTC`s disaffection with agreements not to enter into with an authorized generic drug: (1) If transactions with cash payments are legal, regardless of the form of “compensation,” and (2) a no-deal agreement with an authorized generic drug cannot be distinguished, from a competition perspective, an agreement to provide an exclusive license, which is common and is generally considered to be in the rights of the patent owner. . . .